aTYR PHARMA INC
ATYR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.17
KIRA · Stoqly’s AI analyst, in plain words
- aTYR PHARMA INC had $0.2M of revenue in fiscal 2025, down 19.1% on the year before. Over five years, revenue changed −55.1% a year on average.
- Its operating margin was −40,856.3%, down 11,956.7 pts: of every 100 in sales, about −40,856 is left after running the business.
- aTYR PHARMA INC lost $74.1M in fiscal 2025.
- Free cash flow was −$62.1M in fiscal 2025, −32,664.7% of revenue.
Market cap
$16.2M
P/E
—
Revenue
$0.2M
Net income
−$74.1M
Free cash flow
−$62.1M
Operating margin
−40,856.3%
aTYR PHARMA INC in 30 seconds · fiscal 2025
Are sales growing?
−19.1%
No. Sales fell 19.1% last year.
Does it make a profit?
−39,009.5%
No. It lost money last year.
Does profit turn into cash?
−32,664.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What aTYR PHARMA INC does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- aTYR PHARMA INC
- CIK
- 0001339970
aTYR PHARMA INC · ATYR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $10.4M | $0.4M | $0.2M | $0.2M |
| Revenue growth | −100.0% | — | −96.6% | −33.4% | −19.1% |
| Operating margin | — | −446.8% | −15,557.8% | −28,899.6% | −40,856.3% |
| Net income | −$33.8M | −$45.3M | −$50.4M | −$64.0M | −$74.1M |
| Net margin | — | −436.5% | −14,274.5% | −27,243.8% | −39,009.5% |
| Diluted EPS | −$1.77 | −$1.60 | −$0.94 | −$0.86 | −$0.80 |
| Cash | |||||
| Cash from operations | −$33.1M | −$41.9M | −$33.2M | −$69.1M | −$62.0M |
| Capital expenditure | $0.2M | $1.6M | $4.2M | $0.1M | $0.1M |
| Free cash flow | −$33.3M | −$43.5M | −$37.4M | −$69.2M | −$62.1M |
| FCF margin | — | −419.1% | −10,605.1% | −29,440.0% | −32,664.7% |
| Share count change | 108.3% | 48.9% | 88.6% | 38.5% | 25.2% |
| Debt and strength | |||||
| Cash and short-term investments | $108M | $66.1M | $98.2M | $72.1M | $78.7M |
| Shareholders' equity | $109M | $71.5M | $90.7M | $70.0M | $67.5M |
| Current ratio | 18.9x | 5.8x | 6.3x | 5.5x | 5.3x |
| Returns and quality | |||||
| Return on equity | −47.9% | −50.2% | −62.2% | −79.7% | −107.8% |
| Return on tangible equity | −30.9% | −63.4% | −55.6% | −91.4% | −109.8% |
| Piotroski F-score | 3 | 2 | 3 | 0 | 1 |
| Altman Z'' | 12.0 | −9.8 | −7.8 | −15.3 | −19.5 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
aTYR PHARMA INC · ATYR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.17 a share, the company is worth $16.2M.
Source: SEC EDGAR XBRL filings (CIK 0001339970). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.